{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+risperidone",
    "query": {
      "intervention": "Placebo to risperidone"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 58,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+risperidone&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T12:59:59.770Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03055338",
      "title": "An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia, Acute Episode"
      ],
      "interventions": [
        {
          "name": "Elpipodect",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching MK-8189",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 224,
      "start_date": "2017-03-08",
      "completion_date": "2018-01-09",
      "has_results": true,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-09-26T12:59:59.770Z",
      "location_count": 28,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03055338"
    },
    {
      "nct_id": "NCT00061802",
      "title": "Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "risperidone, quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 225,
      "start_date": "2003-06",
      "completion_date": "2004-02",
      "has_results": false,
      "last_update_posted_date": "2012-02-07",
      "last_synced_at": "2026-09-26T12:59:59.770Z",
      "location_count": 7,
      "location_summary": "San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hoffman Est",
          "state": "Illinois"
        },
        {
          "city": "Lake Charles",
          "state": "Louisiana"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Visakhapatnam",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00061802"
    },
    {
      "nct_id": "NCT00158028",
      "title": "Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizotypal Personality Disorder"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "1995-11",
      "completion_date": "2001-12",
      "has_results": false,
      "last_update_posted_date": "2016-08-04",
      "last_synced_at": "2026-09-26T12:59:59.770Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00158028"
    },
    {
      "nct_id": "NCT01272765",
      "title": "Anti-psychotic Medication (Stable Dose) Weight Loss Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "IHBG-10",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Avera McKennan Hospital & University Health Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-03",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2012-06-01",
      "last_synced_at": "2026-09-26T12:59:59.770Z",
      "location_count": 1,
      "location_summary": "Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272765"
    },
    {
      "nct_id": "NCT00099983",
      "title": "Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stress Disorders",
        "Post-Traumatic"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 296,
      "start_date": "2006-10",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2014-08-22",
      "last_synced_at": "2026-09-26T12:59:59.770Z",
      "location_count": 20,
      "location_summary": "Tuscaloosa, Alabama • San Diego, California • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Los Angeles",
          "state": "California"
        },
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099983"
    },
    {
      "nct_id": "NCT01086748",
      "title": "A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LY2140023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denovo Biopharma LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1134,
      "start_date": "2010-03",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-26T12:59:59.770Z",
      "location_count": 19,
      "location_summary": "Escondido, California • Garden Grove, California • Paramount, California + 16 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01086748"
    },
    {
      "nct_id": "NCT03893825",
      "title": "A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "TV-46000",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "13 Years to 65 Years"
      },
      "enrollment_count": 336,
      "start_date": "2019-04-17",
      "completion_date": "2021-12-02",
      "has_results": true,
      "last_update_posted_date": "2022-12-07",
      "last_synced_at": "2026-09-26T12:59:59.770Z",
      "location_count": 67,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03893825"
    },
    {
      "nct_id": "NCT04567524",
      "title": "A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia Schizoaffective"
      ],
      "interventions": [
        {
          "name": "LYN-005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lyndra Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 34,
      "start_date": "2020-08-13",
      "completion_date": "2020-12-22",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-09-26T12:59:59.770Z",
      "location_count": 5,
      "location_summary": "Long Beach, California • Atlanta, Georgia • Marlton, New Jersey + 2 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Richardson",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04567524"
    },
    {
      "nct_id": "NCT00389493",
      "title": "Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obsessive-Compulsive Disorder"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Exposure/ritual prevention therapy (EX/RP)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 100,
      "start_date": "2006-10",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-04-25",
      "last_synced_at": "2026-09-26T12:59:59.770Z",
      "location_count": 2,
      "location_summary": "New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00389493"
    },
    {
      "nct_id": "NCT02019329",
      "title": "A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "RO5545965",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-01",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-09-26T12:59:59.770Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019329"
    }
  ]
}